Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary obstruction. Its main purpose was to report mortality and stent failure at long term, which remained unknown. 

COMPARE TAVI: Resultados al año de un estudio aleatorizado que compara dos válvulas balón expandibles

Primary end point was long term mortality, while secondary end point was stent failure. This was a multicenter study including patients from 35 centers distributed along three continents. Patients with all kinds of stents or valves participated, in contexts of native aortic stenosis or valve-in-valve procedures, and with traditional or orthotropic chimney stenting.

Participant mean age was 80.9 years. 30.7% of the total procedures were done in native valves, 64.6% were TAV-in-SAV, and 4.7% TAV-in-TAV. Most cases (72.5%), received the classical chimney technique with a stent positioned as protection. 

Patients with established coronary artery obstruction presented significantly more adverse events, mainly death and cardiogenic shock, vs. those treated with coronary obstruction prevention strategies. 

Read also: CCANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx.

The absence of coronary protection was significantly associated with a combined end point of hospital mortality, acute myocardial infarction and cardiogenic shock (OR 8.36; CI95% 3.84-18.18; p≤0.001).

Among mortality predictors at 30 days, the most significant were the presence of established CAD (OR 10.02; p≤0.001) and lack of coronary protection (OR 7.11; p=0.002). On the other hand, long term mortality predictors were stage ≥2 kidney failure (OR 2.32; p=0.039) and access other than femoral. There were no predictors of stent failure. 

Read also: TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation.

Chimney stent failure was low (4%), with no significant differences in events according to coronary prevention strategy. At midterm follow-up, global mortality reached 22.4%.

Presented by Paolo Alberto del Sole at Top Late-Breaking Trials, PCR London Valves, November 24, 2024, London, GB.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...